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Kidney TransplantationPlasma Proenkephalin and Poor Long-Term
Outcome in Renal Transplant Recipients
Lyanne M. Kieneker, MSc,1 Oliver Hartmann, MSc,2 Joachim Struck, PhD,2 Andreas Bergmann, PhD,2
Ron T. Gansevoort, MD, PhD,1 Michel M. Joosten, PhD,1 Else van den Berg, MD, PhD,1
Rudolf A. de Boer, MD, PhD,3 Stephan J.L. Bakker, MD, PhD1Background. Proenkephalin (pro-ENK), a stable and reliable surrogate marker for unstable enkephalins, was found to be as-
sociated with acute kidney injury and chronic renal failure in previous studies. We aimed to investigate whether pro-ENK is linked
to chronic kidney injury and poor long-term outcome in renal transplant recipients (RTR).Methods.We included 664 stable RTR
and 95 healthy kidney donors. Pro-ENK was measured in plasma with a double monoclonal sandwich immunoassay. Graft failure
was defined as return to dialysis therapy or retransplantation. Results. Median pro-ENK was 110 pmol/L (interquartile range
[IQR], 85-148 pmol/L) in RTR and 48 pmol/L (IQR, 42-55 pmol/L) in kidney donors. Pro-ENK was correlated with estimated glo-
merular filtration rate (GFR) (rs = −0.80, P < 0.001) in RTR and with measured GFR (rs = −0.74, P < 0.001) in kidney donors. During
a median follow-up of 3.1 years (IQR, 2.7-3.9 years), 45 RTR developed graft failure and 76 died. Pro-ENK was positively asso-
ciated with risk (hazard ratio [HR] per standard deviation increment of the logarithm of pro-ENK; 95% confidence interval [CI]) of
graft failure (HR, 4.80; 95% CI, 3.55-6.48) and mortality (HR, 1.50; 95% CI, 1.22-1.85). After adjustment of age, sex, and esti-
mated GFR, the association of pro-ENK with graft failure remained significant (HR, 2.36; 95% CI, 1.37-4.06), whereas no signifi-
cant association of pro-ENKwith risk of all-causemortality was observed (HR, 1.34; 95%CI, 0.90-2.09).Conclusions.Plasma
pro-ENK is associated with kidney function as reflected by correlations with measured GFR in both RTR and kidney donors. In
addition, pro-ENK was independently associated with increased risk of graft failure in RTR. Pro-ENK may aid in identification of
RTR at risk for late graft failure.
(Transplantation Direct 2017;3: e190; doi: 10.1097/TXD.0000000000000700. Published online 7 June, 2017.)Enkephalins are well-known endogenous opioid peptidesexhibiting various functions, including involvement in
stress response systems, pain perception, cardiac function,
bone formation, and immune responses.1-5 Enkephalin im-
munoreactivity is also shown to be present in skeletal muscle
myofibers, intestinal smooth muscle cells, and intestinal and
kidney epithelial cells.6 Given that expression of enkephalinReceived 13 March 2017. Revision requested 11 April 2017.
Accepted 7 May 2017.
1 Department of Internal Medicine, University Medical Center Groningen, University
of Groningen, Groningen, the Netherlands.
2 Sphingotec GmbH, Hennigsdorf, Germany.
3 Department of Cardiology, University Medical Center Groningen, University of
Groningen, Groningen, the Netherlands.
Funding Generation of the cohort was made possible by a grant from the Dutch Top
Institute Food and Nutrition.
Conflicts of interest A.B. has shares in and is CEO of sphingotec GmbH, the
company providing and having patent rights on the pro-ENK assay. O.H. and J.S.
are employed by sphingotec GmbH.
L.M.K., O.H., J.S., A.B., R.Ad.B., and S.J.L.B. participated in the concept and
design of the study. E.vd.B. and S.J.L.B. participated in the acquisition of the
data. L.M.K. and O.H. participated in the statistical analyses and writing of the first
draft of the article. J.S., A.B., R.T.G., M.M.J., R.Ad.B., and S.J.L.B. participated in
Transplantation DIRECT ■ 2017receptors in the kidney is dense, it has been hypothesized that
enkephalins may play an important biological function in re-
nal physiology.6
Because enkephalins have a very short half-life, an assay
for a stable precursor fragment of enkephalin, proenkephalin
(pro-ENK) 119 to 159, has been developed and has been estab-
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2 Transplantation DIRECT ■ 2017 www.transplantationdirect.comPro-ENK has been investigated in clinical studies in which el-
evated levels of pro-ENK were associated with prognosis
after acute myocardial infarction,8 acute kidney injury,9 and
chronic renal failure.10 Furthermore, in a recent study, pro-
ENK was found to be associated with a faster decline of renal
function and an increased risk of developing chronic kidney
disease (CKD) in a population-based cohort.11
Because enkephalins have a role in both immunology and
renal damage, we hypothesized that pro-enkephalinmay be a
marker for determining long-term renal prognosis in renal
transplant recipients (RTR). Therefore, the aim of our pres-
ent study was to investigate the association of pro-ENK with
chronic kidney injury and long-term outcome in RTR.MATERIALS AND METHODS
Study Population
All RTRs (aged≥18 years) that were 1 year or longer post-
transplantation were approached for participation during
outpatient clinic visits between 2008 and 2011, as described
previously.12 All RTRs were transplanted in the University
Medical Center Groningen, Groningen, the Netherlands.
None of the RTR underwent desensitization before trans-
plantation, and none of them had a positive crossmatch
before transplantation. Subjects had no history of drug or al-
cohol abuse. Written informed consent was obtained from
707 (87%) from the 817 initially invited RTR. For the pres-
ent analyses, we excluded patients with missing data on
pro-ENK (n = 43), leaving 664 RTR eligible for analyses.
We also included 95 healthy donors, who all gave a kidney
for living renal transplantation and agreed to participate.
The study protocol was approved by the institutional review
board, which adhered to the Declaration of Helsinki. The co-
hort onwhich the studywas based is registered at clinicaltrials.
gov as ‘TransplantLines Food andNutrition Biobank and Co-
hort Study (TxL-FN)’ with number NCT02811835.
Data Collection
The measurement of clinical parameters has been de-
scribed in detail previously.13 Information onmedical history
and medication use was obtained from patient records. Par-
ticipants’ height and weight were measured with participants
wearing indoor clothing without shoes. Body mass index
(BMI) was calculated as weight (kilograms) divided by height
squared (square meter). Blood pressure was measured per
strict protocol as previously described.13 Information on al-
cohol consumption and smoking behavior was obtained by
using a questionnaire. Alcohol consumption was classified
as 0, 0 to less than 10, 10 to 30, or greater than 30 g/d.
Smoking behavior was classified as never, former or current
smoker. Diabetes was defined as use of antidiabetic medica-
tion or fasting plasma glucose of 7.0mmol/L or greater. Phys-
ical activity was assessed with the Short QUestionnaire to
ASsess Health-enhancing physical activity, which has been
developed and validated by the Dutch National Institute of
Public Health and Environment to assess daily life physical
activity in the Dutch adult population.14 Per a strict protocol
at a day before their visit to the outpatient clinic, all RTRs
were asked to collect a 24-hour urine sample. Urine was col-
lected under oil and chlorhexidine was added as an antiseptic
agent. Blood was drawn in the morning after completion of
the 24-hour urine collection. Dietary intake was assessedwith a validated semi quantitative food frequency question-
naire developed by Wageningen University, Wageningen,
the Netherlands. The food frequency questionnaire inquired
about intake of 177 food items during the last month, taking
seasonal variations into account.
Laboratory Procedures
Urine electrolytes were directly analyzed per standard labo-
ratory procedures. Renal function in RTR was estimated with
the combined creatinine cystatin C-based Chronic Kidney Dis-
ease Epidemiology (CKD-EPI) Collaboration equation from
2012.15 In the 95 healthy kidney donors, glomerular filtration
rate (GFR) wasmeasured by constant low dose infusion of the
radiolabeled tracer 125I-iothalamate16,17 and estimated GFR
(eGFR) was estimated with the creatinine-based CKD-EPI
equation.18 Urine albumin was determined by nephelometry
(Dade Behring Diagnostic, Marburg, Germany). Plasma elec-
trolytes and serum cholesterol were measured using standard
laboratory procedures. Serum creatinine was assessed using a
modified version of the Jaffé method (MEGA AU 510; Merck
Diagnostica, Darmstadt, Germany). Class I and class II anti-
human leukocyte antigen antibodies (HLAab), at time of
pro-ENK sampling, were assessed by ELISA (LATM20X5,
One Lambda, Canoga Park, CA).
Measurement of pro-ENK
An assay for stable pro-ENK (amino acids 119-159 of pro-
ENKA) has been previously reported7 andwasmodified as re-
cently described.8 In brief, 2 mousemonoclonal anti-pro-ENK
antibodies were developed by immunization with pro-ENK
peptide (amino acids 119-159 of pro-ENK A). One antibody
(2 μg) was used to coat polystyrene tubes. The other antibody
labeledwithmethyl-acridinium ester served as the detector an-
tibody. Standards (pro-ENK peptide; amino acids 119-159 of
pro-ENKA) and samples (50 μL) were incubated in tubes with
the detector antibody (150 μL). After equilibration, tubes were
washed and bound chemiluminescence was detected with a
luminometer LB952T/16 (Berthold, Bad Wildbad, Germany).
The lower detection limit of the assay was 5.5 pmol/L. Intra-
assay and interassay coefficients of variation were, 6.4% and
9.5% at 50 pmol/L, and 4.0% and 6.5% at 150 pmol/L, re-
spectively. The assay was provided by Sphingotec GmbH
(Hennigsdorf, Germany). Pro-ENK was measured in plasma
at baseline in RTR, and in plasma before (median, 138 days; in-
terquartile range [IQR], 81-242 days), and after transplantation
(median, 50 days; IQR, 49-57 days) in kidney donors.
Outcome Ascertainment
The primary endpoints of this study were all-cause mortal-
ity and death-censored transplant failure, defined as return to
dialysis therapyor retransplantation.The continuous surveillance
system of the outpatient program ensures up-to-date information
on patient status. General practitioners or referring nephrologists
were contacted in case the status of a patient was unknown. End-
points were recorded until the end of May 2013. There was
no loss to follow-up for the primary endpoints.
Statistical Analysis
Baseline characteristics are presented per tertiles of pro-
ENK. Continuous data are presented as mean with SD or
as median and IQR in case of skewed distribution. Categori-
cal data are presented as percentages.
© 2017 Wolters Kluwer Kieneker et al 3Multivariable linear regression was performed to deter-
mine whether patients’ characteristics were associated with
pro-ENK concentrations. In the first model, all analyses were
adjusted for age and sex, the second model was further ad-
justed for eGFR, and the last model included all variables.
The Spearman's rank correlation coefficient was calculated
for the associations of pro-ENK with urinary albumin excre-
tion (UAE), eGFR, and measured GFR (mGFR) (only avail-
able in kidney donors). To study the prospective association
between pro-ENK and risk of graft failure and all-cause mor-
tality, Cox proportional hazards regression analysis was used
to calculate hazard ratios (HRs) per 1 SD increment in log-
transformed values and 95% confidence intervals (CIs). We
first calculated HRs (95% CIs) for the crude model. Second,
we calculated HRs (95% CIs) alternately adjusted for sex,
age, BMI, smoking, high-density lipoprotein (HDL) choles-
terol, triglycerides, serum glucose, antihypertensive drugs,
calcineurin inhibitors, eGFR, or UAE. In the first multivari-
able model, we adjusted for age, sex, and eGFR. In the sec-
ond multivariable model, we additionally adjusted model
1 for BMI, smoking, HDL cholesterol, triglycerides, serum
glucose, antihypertensive drugs, calcineurin inhibitors, and
UAE. In the third multivariable model, we additionally ad-
justed model 1 for time since renal transplantation, donor
status, donor age, cold ischemia time, delayed graft function,
HLAab class I, HLAab class II, rejection type, and cytomeg-
alovirus infection. Nonlinearity was tested by using the like-
lihood ratio test, comparing nested models with linear or
linear and cubic spline terms. We evaluated whether pro-
ENK adds additional prognostic information for risk predic-
tion with the use of the receiver operating characteristic
(ROC) curves for pro-ENK only and for the multivariable
model with and without inclusion of pro-ENK, and by test-
ing on differences in Harrell’s C statistics and −2 Log Like-
lihood of prediction models with and without inclusion of
pro-ENK in the model.
All P values are 2-tailed. A P value less than 0.05 was con-
sidered statistically significant. All analyses were conducted
with the use of the statistical package IBM SPSS (version
22.0.1; SPSS, Chicago, IL), STATA/SE (version 13.1; StataCorp.




Baseline median pro-ENK was 110 pmol/L (IQR, 85-
148 pmol/L), with slightly higher values in women (median,
116; IQR, 87-160 pmol/L) compared with men (median,
106; IQR, 84-148 pmol/L). Baseline characteristics are shown
per tertiles of pro-ENK (Table 1). At baseline, RTRs, who
had a higher pro-ENK, were more likely to be younger and
to have a lower BMI and a smaller waist circumference.
RTRs in the highest tertile of pro-ENK were also more likely
to receive an allograft from a deceased and older donor, to
have a longer cold ischemia time, to be class I and II HLAab
positive, and to have a transplant rejection. Men and women
in the highest tertile of pro-ENK were more likely to have
a lower HDL cholesterol, higher triglycerides, a lower serum
glucose, and to use less antihypertensive medication, including
diuretics, less lipid-lowering drugs, and more calcineurin and
proliferation inhibitors, compared with men and women inthe lowest tertile of pro-ENK. Subjects with high levels of pro-
ENK had lower baseline eGFR and higher UAE.
Pro-ENK was inversely correlated with eGFR (rs = −0.80;
P < 0.001; Figure 1), and creatinine clearance (rs = −0.77;
P < 0.001), and positively with UAE (rs = 0.34; P < 0.001), se-
rum creatinine (rs = 0.72;P < 0.001), and cystatinC (rs = 0.80;
P < 0.001).
Association of pro-ENKWith Selected Variables
Table 2 shows the associations between log-transformed
pro-ENK levels and variables of interest adjusted for (1) age
and sex; (2) age, sex, and eGFR; and (3) multiple variables
of interest. In the analyses adjusted for age and sex, pro-
ENK levels were positively and significantly associated with
current smoking, time since renal transplantation, donor
age, cold ischemia time, positive class I and IIHLAab, triglyc-
erides, cytomegalovirus infection, antihypertensive drug use,
use of lipid-lowering drugs and calcineurin inhibitors, and
UAE. Significant inverse associations with pro-ENK, inde-
pendent of age and sex, were observed for BMI, donor status,
HDL cholesterol, serum glucose, use of proliferation inhibi-
tors, and eGFR. After further adjustment for eGFR, time
since renal transplantation, cold ischemia time, cytomegalo-
virus infection, and UAE were positively associated with
pro-ENK levels, whereas BMI, donor status, donor age, de-
layed graft function, serum glucose, antihypertensive drug
use, and use of calcineurin inhibitors were inversely associated
with pro-ENK. When adding all the variables in the multivar-
iable model, pro-ENK was significantly positively associated
with female sex, whereas inverse associations were observed
with age, BMI, and eGFR.Themultivariablemodel had an ad-
justed R2 of 0.74, with eGFR being the most important con-
tributing determinant (partial R2 = 0.39), indicating that a
large percentage of circulating pro-ENK levels may be ex-
plained by eGFR.
Pro-ENK in Kidney Donors
We included 95 kidney donors (Table S1, SDC, http://links.
lww.com/TXD/A46). Mean age of the healthy donors was
52.4 ±9.7 years, and40%of donorsweremale.MedianmGFR
before donation was 112 mL/min (IQR, 98-133 mL/min), with
a median pro-ENK concentration of 48 pmol/L (IQR, 42-55
pmol/L), whereas the median mGFR postdonation was
72mL/min (IQR, 64-83mL/min),with amedian pro-ENKcon-
centration of 74 pmol/L (IQR, 63-82 pmol/L). Combining data
from pre and postdonation, pro-ENK was inversely correlated
with mGFR (rs = −0.74, P < 0.001; Figure S1, SDC, http://
links.lww.com/TXD/A46), eGFR (rs = −0.68, P < 0.001), and
creatinine clearance (rs = −0.62, P < 0.001), and positively cor-
relatedwith serum creatinine (rs = 0.60, P < 0.001), but not cor-
related with UAE (rs = −0.03, P = 0.64). The percent change in
pro-ENK (between predonation and postdonation) was also in-
versely associatedwith the percent change inmGFR (rs = −0.25,
P = 0.01), whereas the percent change of pro-ENK was not as-
sociated with the percent change in UAE (rs < 0.001, P = 0.99).
Association of pro-ENKWith Risk of Graft Failure and
All-Cause Mortality in RTR
Median follow-up was 3.1 years (IQR, 2.6-3.9 years),
During follow-up, 45 RTR developed graft failure and 76
died. Causes of graft failure are presented in Table S2, SDC,
http://links.lww.com/TXD/A46. Median follow-up was 3.1
(2.7-3.9) years among RTR not developing graft failure,
TABLE 1.
Baseline characteristics per tertiles of plasma pro-ENK of 664 RTRsa
Tertiles of pro-ENK, pmol/L
P value for trendb<38 38-134 >134
Participants, N 221 222 221
Men, % 60.2 56.3 51.6 0.07
Age, y 54.3 ± 11.5 54.3 ± 12.7 50.4 ± 13.8 0.001
BMI, kg/m2 27.5 ± 5.0 26.7 ± 4.5 25.8 ± 4.7 <0.001
Waist circumference, cm 101 ± 14 99 ± 14 96 ± 15 0.003
Current smokers, % 9.5 10.4 14.5 0.10
Alcohol use, never, % 6.8 9.0 10.4 0.18
Primary renal disease 0.74
Primary glomerular disease, % 29.4 29.0 28.1
Glomerulonephritis, % 7.2 7.7 7.2
Tubulointerstitial disease, % 14.5 7.7 12.2
Polycystic renal disease, % 16.7 22.6 22.2
Dysplasia and hypoplasia, % 4.1 4.1 4.5
Renovascular disease, % 4.5 5.0 7.2
Diabetic nephropathy, % 5.0 5.0 5.4
Other or unknown cause, % 18.6 19.0 13.1
Time since renal transplantation, y 5.3 (1.5-11.4) 5.0 (1.7-10.6) 6.2 (2.3-14.3) 0.12
Deceased donor, % 61.0 62.7 74.4 0.003
Donor age, y 39.0 ± 14.9 45.2 ± 15.6 44.2 ± 15.6 0.004
Cold ischemia time, h 12.2 (2.6-19.4) 13.9 (2.6-20.6) 16.5 (3.1-22.0) 0.003
Delayed graft function, % 6.8 5.4 10.9 0.11
Class I HLAab positive, % 8.6 18.0 19.9 0.001
Class II HLAab positive, % 12.7 17.1 23.1 0.004
Mismatches AB, n 0.99
0-1 47.6 48.8 43.2
2-4 52.4 51.2 56.8
Mismatches DR, n 0.91
0-1 85.7 90.9 92.3
2-4 14.3 9.1 7.7
Rejection, % 21.7 23.1 35.7 0.001
T cell mediated, % 7.7 11.3 15.4
Antibody-mediated, % 3.2 1.4 4.1
T cell and antibody-mediated, % 1.8 1.4 2.7
Unknown type, % 8.1 8.6 9.0
Not biopsy proven, % 0.9 0.5 4.5
Dialysis duration, months 35 (21-58) 46 (23-55) 43 (19-66) 0.24
Systolic blood pressure, mm Hg 135 ± 17 136 ± 17 137 ± 18 0.49
Diastolic blood pressure, mm Hg 83 ± 10 81 ± 11 83 ± 12 0.79
LDL cholesterol, mmol/L 2.9 ± 0.9 3.0 ± 0.9 3.1 ± 1.0 0.10
HDL cholesterol, mmol/L 1.4 ± 0.5 1.4 ± 0.5 1.3 ± 0.5 0.01
Triglycerides, mmol/L 1.7 ± 0.8 1.9 ± 0.9 2.1 ± 1.2 0.002
hs-CRP, mg/L 1.6 (0.8-5.0) 1.6 (0.6-4.4) 1.7 (0.8-4.6) 0.61
Diabetes, % 25.8 25.7 20.8 0.22
Glucose, mmol/L 6.0 ± 2.0 5.7 ± 2.1 5.5 ± 1.3 0.04
Cytomegalovirus infection 0.07
No, % 79.2 74.8 70.6
Primary, % 9.5 8.6 14.0
Secondary, % 11.3 16.7 15.4
Antihypertensive drugs, % 86.4 85.1 92.8 0.04
ACEi, % 33.9 30.2 33.0 0.84
Diuretics, % 31.2 41.4 49.3 <0.001
Lipid-lowering drugs, % 2.7 5.0 6.3 0.07
Blood glucose-lowering drugs, % 17.2 15.8 13.1 0.24
Calcineurin inhibitor, % 49.8 55.9 67.4 <0.001
Continued next page
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TABLE 1. (Continued)
Tertiles of pro-ENK, pmol/L
P value for trendb<38 38-134 >134
Cyclosporine, % 39.8 40.5 38.5
Tacrolimus, % 22 34 64
Proliferation inhibitor, % 88.7 83.3 77.8 0.002
Azathioprine, % 14.9 15.3 23.5
Mycophenolic acid, % 73.8 68.0 54.3
Prednisolone, mg/day 8.9 ± 2.0 8.8 ± 1.8 8.6 ± 2.1 0.30
eGFR, mL/min per 1.73 m2 59 (51-70) 42 (35-52) 26 (20-34) <0.001
UAE, mg/24 h 20 (7-89) 28 (8-119) 103 (25-410) <0.001
Serum creatinine, μmol/L 99 (83-116) 123 (105-148) 176 (141-219) <0.001
Serum cystatin C, mg/L 1.3 ± 0.3 1.7 ± 0.4 2.6 ± 0.8 <0.001
a Continuous variables are reported as mean ± SD or median (interquartile range) and categorical variables are reported as percentage.
b Determined by linear-by-linear association chi-square test (categorical variables), linear regression (continuous variables).
ACEi, angiotensin-converting enzyme inhibitor; HLAab, antihuman leukocyte antigen antibodies; hs-CRP, high sensitive C-reactive protein; LDL, low-density lipoprotein.
© 2017 Wolters Kluwer Kieneker et al 5and 1.9 (0.7-2.4) years among RTR developing graft failure.
In the crude analysis without adjusting for covariates, higher
pro-ENKwas associated with increased risk (HR per 1-SD in-
crement of log-transformed pro-ENK; 95%CI) of developing
graft failure (4.80; 3.55-6.48; Table 3; Figure 2A, log-rank
P < 0.001). After adjustment for age, sex, and eGFR, the asso-
ciation with risk of graft failure remained (HR, 2.36; 95%CI,
1.37-4.06; Table 3, Figure 3A). Further adjustment for poten-
tial confounders did not materially affect the association of
pro-ENK with increased risk of developing graft failure (mul-
tivariable model 2: 2.15; 1.08-4.29; multivariable model 3:
2.34; 1.20-4.56; Table 3). The ROC curves (Figure 4) showed
areas under the curve of 0.87 (95% CI, 0.82-0.93), 0.89FIGURE 1. Scatterplot of the associations of plasma pro-ENKwith eGFR
ance (E) in 664 RTRs.(95% CI, 0.84-0.94) and 0.89 (95% CI, 0.84-0.94), re-
spectively for predicting risk of graft failure. When analyzing
the additional prognostic information of pro-ENK for the
prediction of graft failure by comparing Harrell’s C statistics
of prediction models with and without inclusion of pro-
ENK, no significant difference was observed between both
models (P for comparison of multivariable model 1 with
and without inclusion of pro-ENK = 0.84; Table S3, SDC).
However, when investigating differences in the −2 Log Like-
lihood ofmodels with andwithout inclusion of pro-ENK, the
−2 Log Likelihood significantly improved with pro-ENK
included in the model (P for comparison of multivariable
model 1 with and without inclusion of pro-ENK = 0.002;(A), UAE (B), serum creatinine (C), cystatin C (D), and creatinine clear-
TABLE 2.
Multivariable linear regression analysis with log-transformed plasma pro-ENK as dependent variable in 664 RTRs
Age- and sex-adjusted Age-, sex-, and eGFR-adjusted Multivariable adjusted (R2 = 0.74)
Variables Partial R2 Standardized β P value Partial R2 Standardized β P value Partial R2 Standardized β P value
Sex, female vs male — — — — — — 0.002 0.054 0.04
Age, y — — — — — — 0.034 −0.204 <0.001
BMI, kg/m2 0.024 −0.158 <0.001 0.047 −0.219 <0.001 0.040 −0.220 <0.001
Smoking, yes vs no 0.007 0.085 0.03 0.002 0.041 0.07 0.001 0.027 0.28
Time since renal transplantation, y 0.009 0.098 0.01 0.016 0.129 <0.001 0.001 0.040 0.23
Deceased donor, yes vs no 0.020 −0.148 <0.001 0.004 −0.067 0.004 0 0.019 0.68
Donor age, y 0.03 0.168 <0.001 0.007 −0.085 <0.001 0.001 −0.042 0.18
Cold ischemia time, hour 0.029 0.175 <0.001 0.013 0.117 <0.001 0.001 0.072 0.13
Delayed graft function, yes vs no 0.002 0.041 0.29 0.003 −0.054 0.02 0 −0.011 0.67
Class I HLAab positive, yes vs no 0.010 0.103 0.01 0 0.022 0.33 0 0.017 0.52
Class II HLAab positive, yes vs no 0.019 0.139 <0.001 0.002 0.043 0.06 0 0.012 0.66
Rejection, yes vs no 0.019 0.140 <0.001 0.002 0.041 0.07 0.001 0.027 0.32
LDL cholesterol, mmol/L 0.004 0.063 0.10 0 0.015 0.51 0.001 0.032 0.20
HDL cholesterol, mmol/L 0.015 −0.130 0.001 0.002 0.042 0.08 0 0.002 0.95
Triglycerides, mmol/L 0.025 0.157 <0.001 0.001 −0.036 0.12 0 0.022 0.46
Hs-CRP, mg/L 0.002 0.050 0.21 0 −0.022 0.35 0 0.008 0.74
Glucose, mmol/L 0.009 −0.097 0.01 0.003 −0.060 0.007 0 −0.023 0.35
Cytomegalovirus infection, yes vs no 0.009 0.096 0.012 0.007 0.082 <0.001 0 0.001 0.96
Antihypertensive drugs, yes vs no 0.014 0.121 0.002 0.004 −0.062 0.007 0 −0.010 0.70
Lipid-lowering drugs, yes vs no 0.007 0.085 0.03 0 −0.004 0.87 0 −0.001 0.98
Calcineurin inhibitor, yes vs no 0.015 0.124 0.001 0.006 −0.079 0.001 0.001 −0.043 0.12
Proliferation inhibitor, yes vs no 0.012 −0.108 0.005 0 0.006 0.78 0 0.024 0.35
eGFR, mL/min per 1.73 m2 0.648 −0.810 <0.001 — —- — 0.389 −0.824 <0.001
UAE, mmol/24 h 0.125 0.360 <0.001 0.004 0.065 0.007 0.001 0.030 0.26
TABLE 3.
Association between plasma pro-ENK and risk of graft failure in 664 RTRs.a
Log pro-ENK Categories of pro-ENK, pmol/L
per 1-SD increment <180 180-290 >290
Number 664 563 79 22
Person-years 2036 1785 210 40
Cases 45 15 15 15
Crude model 4.80 (3.55-6.48) 1.00 (reference) 8.62 (4.21-17.65) 45.92 (22.35-94.35)
+Sex 4.96 (3.64-6.77) 1.00 (reference) 9.01 (4.38-18.55) 48.36 (23.35-100.16)
+Age 5.12 (3.70-7.08) 1.00 (reference) 9.02 (4.38-18.55) 53.88 (24.40-118.96)
+BMI 4.99 (3.63-6.87) 1.00 (reference) 8.69 (4.22-17.89) 46.86 (22.11-99.33)
+Smoking 5.38 (3.85-7.51) 1.00 (reference) 8.69 (4.21-17.93) 55.30 (26.00-117.63)
+HDL cholesterol 4.91 (3.61-6.70) 1.00 (reference) 8.62 (4.21-17.66) 47.30 (22.97-97.40)
+Triglycerides 4.82 (3.56-6.53) 1.00 (reference) 8.40 (4.07-17.34) 46.03 (22.39-94.60)
+Serum glucose 5.01 (3.69-6.80) 1.00 (reference) 9.55 (4.57-19.95) 51.05 (24.34-107.07)
+Antihypertensive drugs 4.79 (3.54-6.47) 1.00 (reference) 8.34 (4.07-17.09) 46.98 (22.83-96.67)
+Calcinurin inhibitors 5.15 (3.71-7.15) 1.00 (reference) 7.42 (3.60-15.29) 58.11 (27.63-122.23)
+eGFR 2.63 (1.67-4.15) 1.00 (reference) 1.63 (0.70-3.87) 6.37 (2.58-15.74)
+UAE 3.73 (2.67-5.22) 1.00 (reference) 6.12 (2.91-12.86) 18.19 (7.73-42.77)
Multivariable model 1b 2.36 (1.37-4.06) 1.00 (reference) 1.50 (0.64-3.54) 4.92 (1.77-3.54)
Multivariable model 2c 2.11 (1.06-4.23) 1.00 (reference) 1.36 (0.55-3.36) 3.64 (1.11-11.95)
Multivariable model 3d 3.20 (1.56-6.58) 1.00 (reference) 2.06 (0.79-5.39) 6.86 (1.82-25.92)
a HRs were derived from Cox proportional hazards models.
b Multivariable model 1 includes age, sex, and eGFR.
c Multivariable model 2 is adjusted for variables in model 1 + BMI, smoking, HDL cholesterol, triglycerides, serum glucose, antihypertensive drugs, lipid lowering drugs, calcineurin inhibitors, and UAE.
d Multivariable model 3 is adjusted for variables in model 1 + time since renal transplantation, donor status, donor age, cold ischemia time, delayed graft function, HLAab class I, HLAab class II, rejection type,
proliferation inhibitors, and cytomegalovirus infection.
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FIGURE 2. Kaplan Meier curves for graft failure (A) and all-cause mortality (B) per tertiles of plasma pro-ENK in 664 RTRs.
© 2017 Wolters Kluwer Kieneker et al 7Table S3, SDC, http://links.lww.com/TXD/A46), indicating
that the models including pro-ENK had a higher predictive
capacity.
In crude analysis, higher pro-ENK was associated with in-
creased risk of all-cause mortality (HR, 1.50; 95% CI, 1.22-
1.85, Table 4, Figure 2B). However, after adjustment for age,
sex, and eGFR, this association was not significant anymore
(1.37; 0.90-2.09; Table 4; Figure 3B). Further adjustment for
other variables did not materially change the association
(multivariable model 2: 1.45; 0.83-2.53; multivariable model
3: 1.49; 0.92-2.40; Table 4).DISCUSSION
In this prospective cohort study of RTR, we investigated
the association of pro-ENK with chronic kidney injury and
long-term outcome. Our results show that plasma pro-ENK
is associated with kidney function as reflected by correlations
with eGFR and UAE in RTR and with mGFR in healthy kid-
ney donors. Furthermore, our results demonstrate that high
pro-ENK is associated with increased risk of graft failure in-
dependent of eGFR, UAE, and other potential determinants
of graft failure. Pro-ENK was not independently associated
with risk of all-cause mortality.
Our data are consistent with the observations of Smith
et al, Zoccali et al, and Marino et al9,10,19,20 that plasma en-
kephalins are markedly elevated in patients with chronic or
acute renal failure compared to healthy subjects. We foundFIGURE 3. Associations of plasma pro-ENKwith risk of graft failure (A) a
portional hazards regressionmodels based on restricted cubic splines with
the 95%CIs. The spline curve is truncated at the 0.5th and 99.5th percent
pro-ENK was 2.04. P values for nonlinear association are P = 0.10 for papro-ENK concentrations to be lower in healthy kidney do-
nors compared toRTR, both before and after donation. After
donation, pro-ENK concentrations increased in the healthy
donors, whereas their kidney function decreased after dona-
tion. The correlations of pro-ENK with eGFR in RTR and
with mGFR in healthy donors were very strong (rs = −0.80
and rs = −0.74, respectively), and are in line with prior studies
which also included patients with acute or chronic renal
failure.9,10,19,20
Next to kidney function as the major determinant of pro-
ENK observed in previous studies as well as in the present
study, also age, sex, and BMI were significantly associated
with pro-ENK after multivariable adjustment. These findings
are consistent with previous literature.8,11,21 In a diabetic
population, in healthy men and women, and in patients with
acutemyocardial infarction positive associations of pro-ENK
were observed with age, female sex, and an inverse asso-
ciations were observed for pro-ENK with BMI, crude8,11 or
multivariable adjusted with inclusion of albuminuria as
marker of kidney function.21
This study is the first to prospectively examine the poten-
tial association of pro-ENK with risk of graft failure and
all-cause mortality in RTR. In a recent study of Schulz al,11
the association of pro-ENK with changes in renal function
per year and risk of developing CKD was examined in
2568 participants of theMalmöDiet and Cancer study. They
observed that high levels of plasma pro-ENKwere associated
with deterioration of kidney function and incidence of CKD.nd risk of all-cause mortality (B) in 664 RTRs. Data were fit by Cox pro-
3 knots and adjusted for age, sex, and eGFR. The grey areas indicate
ile of the distribution curve. Reference standard for the log-transformed
nel A, and P = 0.36 for panel B.
FIGURE 4. ROC curves of the association of pro-ENK with risk of graft failure in 664 RTRs. Dashed lines indicate the empirical curve, solid
diagonal lines indicate no discrimination. Panel A represents the AUC for pro-ENK only. Panel B represents the AUC for age, sex, and eGFR.
Panel C represents the AUC for age, sex, eGFR, and pro-ENK. AUC, area under the curve.
8 Transplantation DIRECT ■ 2017 www.transplantationdirect.comIn a study of Shah et al, preoperative pro-ENK was associ-
ated with postoperative AKI in patients undergoing cardiac
surgery.20 They hypothesized that the association reflects
common cellular mechanisms, including inflammation, which
causes AKI and pro-ENK release into the circulation. How-
ever, in a study of Marino et al, pro-ENKwas associated with
presence and severity of AKI in hospitalized patients with sep-
sis, independent from inflammation, as opposed to themarker
neutrophil gelatinase-associated lipocalin.9
In the study ofMarino et al,9 most patients without AKI or
at risk had pro-ENK levels below the 99th percentile of the
normal range (80 pmol/L). In our present study, higher riskTABLE 4.






Crude model 1.50 (1.22-1.85) 1.00
+Sex 1.51 (1.22-1.87) 1.00
+Age 1.79 (1.42-2.26) 1.00
+BMI 1.52 (1.23-1.89) 1.00
+Smoking 1.60 (1.29-1.98) 1.00
+HDL cholesterol 1.44 (1.16-1.78) 1.00
+Triglycerides 1.48 (1.20-1.84) 1.00
+Serum glucose 1.55 (1.26-1.91) 1.00
+Antihypertensive drugs 1.48 (1.20-1.83) 1.00
+Calcinurin inhibitors 1.51 (1.22-1.87) 1.00
+eGFR 0.84 (0.58-1.22) 1.00
+UAE 1.46 (1.16-1.85) 1.00
Multivariable model 1b 1.37 (0.90-2.09) 1.00
Multivariable model 2c 1.48 (0.92-2.40) 1.00
Multivariable model 3d 1.53 (0.94-2.50) 1.00
a HRs were derived from Cox proportional hazards models.
b Multivariable model 1 includes age, sex, and eGFR.
c Multivariable model 2 is adjusted for variables in model 1 + BMI, smoking, HDL cholesterol, triglycerides
d Multivariable model 3 is adjusted for variables in model 1 + time since renal transplantation, donor statu
proliferation inhibitors, and cytomegalovirus infection.of graft failure was only observed for RTR with the highest
pro-ENK concentrations (>134 pmol/L, Figure 2), which are
increased concentrations compared to the median pro-ENK
concentrations in the healthy kidney donors (48 pmol/L).
The strong correlations of pro-ENKwith eGFR andmGFR
suggest that pro-ENK is a good marker for renal function.
However, in the present study we also observed an asso-
ciation of pro-ENK with risk of developing graft failure in
RTR, independent of eGFR. These results could indicate an
independent and added value of pro-ENK in the identifica-
tion of RTR at risk for graft failure. Arguably, the association
observed could also be the result of residual confoundingality in 664 RTRs.a





(reference) 1.32 (0.76-2.28) 2.56 (1.47-4.45)
(reference) 1.33 (0.77-2.31) 2.59 (1.49-4.53)
(reference) 1.39 (0.80-2.41) 3.16 (1.81-5.50)
(reference) 1.34 (0.77-2.32) 2.62 (1.50-4.59)
(reference) 1.42 (0.81-2.47) 2.90 (1.66-5.08)
(reference) 1.26 (0.73-2.18) 2.25 (1.29-3.95)
(reference) 1.30 (0.75-2.25) 2.46 (1.40-4.32)
(reference) 1.38 (0.80-2.39) 2.80 (1.60-4.91)
(reference) 1.29 (0.74-2.23) 2.45 (1.41-4.27)
(reference) 1.35 (0.77-2.34) 2.65 (1.51-4.66)
(reference) 0.56 (0.29-1.08) 0.54 (0.23-1.29)
(reference) 1.31 (0.75-2.29) 2.35 (1.28-4.30)
(reference) 0.71 (0.36-1.42) 0.96 (0.39-2.38)
(reference) 0.71 (0.34-1.48) 1.00 (0.37-2.72)
(reference) 0.77 (0.36-1.68) 1.06 (0.38-2.94)
, serum glucose, antihypertensive drugs, lipid lowering drugs, calcineurin inhibitors, and UAE.
s, donor age, cold ischemia time, delayed graft function, HLAab class I, HLAab class II, rejection type,
© 2017 Wolters Kluwer Kieneker et al 9with respect to pro-ENK as amarker for renal function in ad-
dition to eGFR as a marker for renal function. Importantly,
in the genome wide association study performed by Schulz
et al,11 they identified genetic variation at the PENK locus
that associated with higher pro-ENK levels and with longitu-
dinal deterioration of kidney function and higher incidence
CKD, suggesting a causal relationship between pro-ENK
and CKD. When comparing prediction models by means of
Harrell’s C statistics and ROC curves for models with and
without inclusion of pro-ENK, we found no significant dif-
ference in predictive value for the model with inclusion of
pro-ENK compared to the model without inclusion of pro-
ENK. Like ROC curves for cross-sectional analyses, their
time-to-event equivalent of Harrell’s C-statistics, is based
on ranks rather than on continuous data, making them very
insensitive for detection of differences.22,23 To avoid injudi-
cious discarding of otherwise promising markers, it is there-
fore currently recommended to also compare prediction
models by means of more sensitive methods, like the −2
Log Likelihood.22,23 Using this method, we indeed found a
significant difference between both prediction models, indi-
cating that pro-ENK adds prognostic value.
Because of the small molecular weight of pro-ENK
(4586.60 g/mol), it is very likely that it is mainly cleared by
the kidney. The association of enkephalins with renal disease
therefore likely implies impaired clearance or increased pro-
duction of enkephalins in renal disease. Besides inflamma-
tion, various other physiological functions have been shown
to be modulated by enkephalins, including processes of cell
growth, differentiation, and apoptosis.4,6,24,25 In an experi-
mental study in conscious Sprague-Dawley rats, activation
of the delta opioid system by infusion of a delta opioid recep-
tor agonist stimulated kidney function.26 We could therefore
speculate that an increment in pro-ENK concentrations could
reflect counteracting the decreasing functionality of the kid-
ney by promoting kidney function. However, further experi-
mental studies blocking or stimulating the opioids receptors
are needed to investigate the potential role of pro-ENK in this
relationship.
A limitation of this study is that pro-ENK was measured
only once at baseline and, therefore, we could not consider
changes over time in pro-ENK concentrations. However,
when the intraindividual variability of variables is consid-
ered, this results in strengthening of associations.27,28 There-
fore, our use of a single pro-ENK measurement at baseline
rather thanmultiple ones, will likely provide an underestima-
tion of the true effect. Second, we only had data on eGFR as
measure of kidney function in RTR. This is a less precisemea-
sure for renal function compared to mGFR. Third, we did
not have complete data on specific cause of chronic allograft
dysfunction (ie, antibody-mediated rejection of transplant
glomerulopathy) since it is not standard to perform a biopsy
to discern cause of graft failure mostly because it is then
judged to not have any clinical consequences or too late in
course of decline of renal function to allow for obtaining con-
clusive material. Fourth, we did not have information about
whether the HLAab were donor-specific. Finally, our results
of an association between pro-ENK and risk of graft failure
may not be readily generalizable to newly transplanted pa-
tients, because of the relatively mature stage of sampling of
the RTR (all RTR >1 year after transplantation, with the ma-
jority >5 years).Strengths of this study are the prospective design, the rela-
tively large cohort of a specific patient group consisting of
well-characterized, stable RTR and the complete follow-up
for both endpoints.
In conclusion, plasma pro-ENK is associated with kidney
function as reflected by correlations with eGFR and UAE in
RTR and with mGFR in healthy kidney donors. In addition,
pro-ENK was independently associated with increased risk
of graft failure in RTR. Pro-ENK may aid in early identifica-
tion of RTR at risk for late graft failure who could benefit
from closer monitoring.REFERENCES
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